Continuing their mission to deliver the most pioneering cancer treatments to India at accessible prices, the Thane-based SunAct Cancer Institute has forged a partnership with Malaysian innovators Abgentil Biomedical SDN BHD to roll out CAR-T, TCR, and TIL therapies for solid tumors across the nation. This landmark agreement was officially executed at SunAct’s facility in Thane, with the signing led by the esteemed founder and oncologist Dr. Vijay Patil and Abgentil Biomedical’s managing director, Loh Hui Pin.
In his remarks, Dr. Patil expressed, “We are thrilled to have successfully brought this groundbreaking cancer treatment for solid tumors to Indian shores swiftly. A special thanks to Loh for dedicating her valuable time to be here in India for what is in many ways a historical event. As leaders in CAR-T, TCR, TIL, and other transformative cancer therapies, Abgentil’s involvement brings renewed hope to many patients and their caregivers.”
Loh Hui Pin shared her sentiments, adding, “It’s an honor that Abgentil is collaborating with Dr. Patil and SunAct to introduce this recent breakthrough therapy for solid-state malignancies in India. Dr. Patil and his team possess deep knowledge and a fervent ambition to fight cancer not just in India but globally. We are optimistic that this alliance will greatly benefit patients in India specifically.”
Highlighting the deal’s importance, Dr. Patil pointed out, “Data shows that the majority of cancers identified in our country are solid tumors, including head and neck, breast, and lung cancers. Unfortunately, these are often detected late, which means that despite using surgery, radiation, chemotherapy, targeted therapy, and immunotherapy, many cases remain untreatable. In such scenarios, exploring alternative and advanced treatment solutions becomes crucial. Adoptive cellular therapies, such as CAR-T, TCR, and TIL, symbolize hope. TIL therapy, for instance, is FDA-approved for melanoma with impressive results, and TCR therapies have recently been authorized for treating sarcoma when chemotherapy fails. However, accessing these groundbreaking therapies in India remains challenging. At SunAct, we aim to alter this scenario.”
Being the nation’s pioneer in offering contemporary CAR-T Cell Therapy and TCR for solid tumors, the Thane clinic will soon elevate its status by further enhancing its advanced cancer treatment offerings in India.
SunAct Cancer Institute’s undying dedication to expanding cancer care accessibility and bringing forth innovative treatment possibilities is set to be realized in several Indian cities. Centers are expected to launch in Khar/Bandra (Mumbai) next year, followed by expansions in Pune, Delhi/NCR, Bengaluru, and other major cities in the coming five years.
In the ongoing fight against cancer, CAR-T cell therapy arises as a revolutionary treatment strategy, gifting new hope to patients grappling with severe and challenging malignancies.
The SunAct Cancer Institute boasts a devoted team of oncologists and medical experts led by Dr. Vijay Patil, dedicated to providing state-of-the-art cancer treatments utilizing advanced technologies to patients worldwide, all at a fraction of the cost. Spearheaded by Dr. Patil, a leading Medical Oncologist and prolific author with over 660 research papers, who has also been associated with renowned institutions like Tata Memorial Centre and P.D. Hinduja Hospital, Mumbai.